Gilead Sciences hits a 52-week high buoyed by investor optimism. We believe there is still room for growth and recommend the ...

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

We recently published a list of 13 Most Undervalued NASDAQ Stocks To Buy According To Hedge Funds. In this article, we are going to take a look at where Gilead Sciences, Inc.

Gilead’s Sandra Patterson has “decided to leave the company” after two years in the SVP corporate controller and chief ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the ...

Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on ...

Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...

Wall Street’s high-flying northward journey from January 2023 to January 2025 was predominantly supported by an astonishing ...

Additional Phase 2 data for vilastobart,a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC ...

Valued at a market cap of $143.8 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company that discovers, ...